In vivo- und in vitro-Komplementaktivierung durch den monoklonalen CD20-Antikörper Rituximab bei der Behandlung von  Non-Hodgkin-LymphomenChristian GereckeI1.1.1121.2341.3561.471.58548#2821.6910111.712131.8548#282142.2.1142.2152.31617783#5452.41819202.52.6212.722232.824253.3.126399#43627399#43628451#447440#43929467#44730437#44031355#3723.232588#468574#45833566#49734592#4873.3353637451#396510#42238480#4304.4.138394041424.2434445464.3475.48495051526. Abkürzungsverzeichnis7. Literaturverzeichnis Eidesstattliche Erklärung DanksagungdeInhaltsverzeichnisHilfe 7. Literaturverzeichnis

7.1 Bücher

1. Fauci A.S., Braunwald E., Isselbacher K.J., Wilson J.D., Martin J.B., Kasper D.L., Hauser S.L., Longo D.L. (1999): Harrisons Innere Medizin. 14. Auflage McGraw-Hill Internatinal (UK) Ltd. 2. Fuchs R. (1997): Diagnostik und Therapie lymphatischer Neoplasien. 3. Bortz J., Lienert G.A. (1998): Kurzgefasste Statistik für die klinische Forschung.
Heidelberg:
Springer 4. Janeway C.A., Travers P., Walport M., Capra J.D. (1999): Immunobiologie. 4. Auflage,
New York
 5. Schmoll H.-J., Höffken K., Possinger K. (1999): Kompendium Internistische Onkologie 3. Auflage, Springer Verlag 6. Paumgartner G.: Therapie innerer Krankheiten. 9. Auflage, Springer Verlag

7.2 Zeitschriften

7. Devesa S.S., Fears T . (1992) Non-Hodgkin`s Lymphoma Time Trends: United States and International Data. Cancer Research 52 (Suppl.19): 5432-5440 8. Devesa S.S., Blot W.J., Stone B.J., Miller B.A., Tarone R.E., Fraumeni F., Jr. (1995) Resent Cancer Trends in the United States. Journal National Cancer Institut 87: 175-182 9. Hardell L., Ericsson M. (1999) A case- control study of non-Hodgkin lym phoma and exposure to pesticides. Cancer 85 (6): 1353-1360 10. Khorana A.A., Rosenblatt J.D., Young F.M. (2001): Immunopathogenesis of HIV and HTLV-1 infection: mechanisms for lymphomagenesis. Cancer Treatment Research 104: 19-74 11. Du M.Q., Diss T.C., Liu H. et al. (2002) KSHV- and EBV-associated germinotropic lymphoproliferative disorder. Blood 100 (9):3415-3418 12. Le Beau M.M. (1990) Chromosomal abnormalities in non-Hodgkin’s lymphomas. Seminars in Oncology 17: 20-29 13. Gerhard-Marchant R., Hamlin I., Lennert K., Rilke F., Stansfeld A., van Unnik J .(1974) Classification of non-Hodgkin lymphomas. Lancet 2: 406-408 14. Stansfeld A., Diebold J., Kapanci Y., et al. (1988) Updated Kiel classification for lymphomas. Lancet 1: 292-293 15. Lennert K., Feller A. (1992) Histopathology of Non-Hodgkin’s Lymphomas. New York: Springer Verlag 16. Rappaport H. (1966) Atlas of tumor pathology, section III, fascicle 8.
Armed Forces Institute of Pathology.
 17. The Non-Hodgkin’s Lymphoma Classification Project: National Cancer Insti tute sponsored study of classification of Non-Hodgkin’s lymphomas: summary and description of a Working Formulation for clinical usage. (1982) Cancer 49: 2112-2135 18. Harris N.L., Jaffe E.S., Stein H. et al. (1994) A revised European-American classification of lymphoid neoplasms: a proposal from the International Lym phoma Study Group. (1994) Blood 84: 1361-1392 19. Jaffe E.S., Harris N.L., Diebold J., Müller-Hermelink H.K. (1998) World Health Organisation Classification of lymphomas: A work in progress. Annals of Oncology 9 (suppl.5): 25-30 20. Stein H., Hiddemann W. (1999) Die neue WHO-Klassifikation der malignen Lymphome Deutsches Ärzteblatt 96, Heft 49 A3168-3176 21. Carbone P.P., Kaplan H.S., Musshoff K., Smithers D.W., Tubina M. (1971) Report of the committee on Hodgkin’s disease staging classification. Cancer Research 31: 1860-1861 22. Stuschke M., Hoederath A., Sack H., Potter R., Müller R.P., Schulz U., Karstens J., Makoski H.B. (1997) Extended field and total central lymphatic radiotherapy in the treatment of early stage lymph node centroblastic-centro cytic lymphomas: results of a prospective multicenter study. Cancer 80: 2273-2284 23. MacManus M.P., Hoppe R.T. (1996) Is radiotherapy curative for stage I or II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. Journal of Clinical Oncology 14: 1282-1290 24. Vaughan-Hudson B., Vaughan-Hudson G., MacLennan K.A. (1994) Clinical stage I non-Hodgkin’s lymphoma: Long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy. British Journal of Cancer 69: 1088-1093 25. Hiddemann W., Dreyling M., Unterhalt M. (2001) Aktuelle Entwicklungen in der Therapie follikulärer Keimzentrumslymphome. Der Onkologe 7: 969-981 26. Biermann P., Vose J.M., Anderson J.R., Bishop M.R. Kessinger A., Armitage J.O. (1997) High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin’s lymphoma. Journal of clinical Oncology 15: 445-450 27. Coiffier B., Lepage E., Brière J. et al. (2002) CHOP-Chemotherapie plus Rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine 346: 235-242 28. Pfreundschuh M., Truemper L., Schmits R. (2002) 2-weekly vs. 3-weekly CHOP with and without Etoposide in Young Patients with Low-Risk (low LDH) Aggressive Non-Hodgkin's Lymphoma: Results of the Completed NHL-B-1 Trial of the DSHNHL.
ASH 2002
; Abstract #340 29. Wunderlich A., Kloess M., Reiser M. et al. (2003) Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Annals of Oncology 14 (6): 881-893 30. Köhler G., Milstein C., (1975) Continuous cultures of fused cells secreting anti body of pre-defined specificity. Nature 256: 652-661 31. Press O.W., Appelbaum F., Ledbetter J.A. et al. (1987) Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 69 (2): 584-591 32. Foon K.A. (2000) Monoclonal Antibody Therapies for lymphomas. The Cancer Journal 6 (5): 273-277 33. Coiffier B. (1999) Monoclonal antibodies in the treatment of non-Hodgkin’s lymphoma. Haematologica 84 (14-18) 34. Quesada J.R., Reuben J., Manning J.T., Hersh E.M., Gutterman J.U. (1984) Alpha interferon for induction of remission in hairy cell leukaemia. New England Journal of Medicine 310: 15-28 35. Golomb H.M., Jacobs A., Fefer A. et al. (1986) α -2-interferon therapy of hairy-cell leukemia: a multicenter study of 64 patients. The Journal of Clinical Oncology 4: 900-905 36. Mantovani L., Guglielmi C., Martelli M., Chierichini A. et al. (1989) Recombinant alpha interferon in the treatment of low- grade non-Hodgkin’s lymphoma: results of a cooperative phase II trial in 31 patients. Haematologica 74 (6) 571-5 37. Hagenbeek A., Carde P., Meerwaldt J.H., Somers R. et al. (1998) Maintenance of remission with human recombinant interferon alpha-2a in patients with stages III and IV low-grade malignant non Hodgkin’s lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. Journal of Clinical Oncology 16 (1) 41-47 38. Anderson J.W., Smalley R.V. (1993) Interferon alpha plus chemotherapy for non-Hodgkin’s lymphoma: five year follow-up. New England Journal of Medicine 329: 1821-1822 39. Solal-Celigny P., Lepage E., Brousse N., et al. (1993) Recombinant interferon alpha-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. New England Journal of Medicine 329: 1608-1614 40. Unterhalt M., Hermann R., Koch P., Trümper L. et al. for the German Low Grade NHL Study Group (1996) Long term interferon alpha maintenance prolongs remission duration in advanced low grade lymphomas and is related to the efficacy of initial cytoreductive chemotherapy. Blood 88 (Suppl.1): 453a 41. Hiddemann W., Griesinger F., Unterhalt M. (1998) Interferon alpha for the treatment of follicular lymphomas. The Cancer Journal from Scientific American; 4 (Suppl. 2): 13-18 42. Stashenko P., Nadler L.M., Hardy R., Schlossman S.F. (1980) Characterization of a human B lymphocyte-specific antigen. The Journal of Immunology 125 (4): 1678-1685 43. Tedder T.F., Klejman G., Disteche C.M., Adler D.A., Schlossman S.F., Saito H. (1988) Cloning of a complementary DNA encoding a new mouse B lymphocyte differentiation antigen, homologous to the human B1(CD20) antigen, and localization of the gene to chromosome 19. The Journal of Immunology 141 (12): 4388-4394 44. Tedder T.F., Disteche C.M., Louie E., Adler D.A., Croce C.M., Schlossman S.F., Saito H. (1989) The gene that encodes the human CD20 (B1) differentiation antigen is located on chromosome 11 near the t(11;14)(q13;q32) translocation site. The Journal of Immunology 142 (7): 2555-2559 45. Tedder T.F., Klejman G., Schlossman S.F., Saito H. (1989) Structure of the gene encoding the human B lymphocyte differentiation antigen CD20 (B1) The Journal of Immunology 142 (7): 2560-2568 46. Tedder T.F., Boyd A.W., Freedman A.S., Nadler L.M., Schlossman A.F. (1985) The B-cell surface molecule B1 is functionally linked with B-cell activation and differentiation. The Journal of Immunology 135 (2): 973-979 47. Tedder T.F. and P. Engel (1994) CD20: a regulator of cell-cycle progression of B lymphocytes. Immunology Today 15 (9): 450-454 48. Bubien J.K., Zhou L.J., Bell D., Frizzell R.A. and T.F. Tedder (1993) Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes. The Journal of Cell Biology 121 (5): 1121-1132 49. Elisabeth Genot (1994) Interferon alpha and intracytoplasmic free calcium in hairy cell leukaemia cells. Leukemia and Lymphoma 12:373-381 50. Genot E., Bismuth G., Degos L., Sigaux F., Wietzerbin J. (1992) Interferon alpha downregulates the abnormal intracytoplamic free calcium concentration of tumor cells in hairy cell leukemia. Blood 80 (8): 2060-2065 51. Deans J.P., Schieven G.L., Shu G.L., Valentine M.A., Gilliland L.A., Aruffo A., Clark E.A., Ledbetter J.A. (1993) Association of tyrosine and serine kinases with the B cell surface antigen CD20. The Journal of Immunology 151 (9) 4494-4504 52. Shan D., Ledbetter J.A. and Oliver W. Press (1998) Apoptosis of malignant human B cells by Ligation of CD20 with monoclonal antibodies. Blood 91(5): 1644-1652 53. Golay T.J., Clark A.E., Beverley P.C.L. (1985) The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle. The Journal of Immunology 135 (6): 3795-3801 54. Tedder T.F., Forsgren A., Boyd A.W., Freedman A.S., Nadler L.M., Schlossman S.F. (1986) Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B-lymphocytes. European Journal of Immunology 16:881-887 55. Winkler U., Schnell R., Engert A. (1999) Einsatz monoklonaler und bispezifischer Antikörper in der Tumortherapie. Der Onkologe 5: 679-687 56. Reff M.E., Carner K., Chambers K.S., Chinn P.C., Leonard J.E., Raab R., Newman R.A., Hanna N., Anderson D.R. (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83 (2): 435-445 57. Maloney D.G., Smith B., Appelbaum F.R. (1996) The anti-tumor effect of monoclonal anti-CD20 antibody therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin’s lymphoma cell lines. Blood 88 (Suppl.):637a 58. Demidem A., Hanna N., Hariharan H., Bonavida B. (1995) Chimeric anti-CD20 antibody (IDEC C2B8) is apoptotic and sensitizes drug-resistant human B-cell lymphoma and AIDS-related lymphomas to the cytotoxic effect of CDDP, VP-16 and toxins. FASEB Journal 9: A206 59. Demidem A., Lam T., Alas S., Hariharan K., Hanna N., Bonavida B. (1997) Chimeric anti-CD20 (IDEC C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biotherapy and Radiopharmaceuticals 12 (3): 177-186 60. Maloney D.G., Grillo-Lopez A.J., Bodkin D.J., White C.A., Liles T.M., Royston I., Varns C., Rosenberg J., Levy R. (1997) IDEC C2B8: results of a phase I multiple- dose trial in patients with relapsed non-Hodgkin’s lymphoma. Journal of Clinical Oncology 15 (10): 3266-3274 61. Maloney D.G., Grillo-Lopez A.J., White C.A., Bodkin D., Schilder R.J., Neidhart J.A., Janakiraman N., Foon K.A., Liles T.M., Dallaire B.K., Wey K., Royston I. Davis T., Levy R. (1997) IDEC C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’ lymphoma. Blood 90 (6): 2188-2195 62. McLaughlin P., Grillo-Lopez A.J., Link B.K., Levy R., Czuczman M.S. et al. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. The Journal of Clinical Oncology 16 (8): 2825-2833 63. Feuring-Buske M., Kneba M., Unterhalt M., Engert A. et al. (2000) IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group. Annals of Hematology 79:493-500 64. Hainsworth J.D., Burris III H.A., Morrissey L.H., Litchy S. et al. (2000) Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 95 (10): 3052-3056 65. Tobinai K., Kobayashi Y., Narabayashi M., Ogura M. and members of the IDEC C2B8 study group (1998) Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC C2B8) in relapsed B cell lymphoma. Annals of Oncology 9: 527-534 66. Foran J.M., Gupta R.K., Cunningham D. et al. (2000) A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. British Journal of Haematology 109: 81-88 67. Hainsworth J.D., Litchy S., Burris H.A. 3rd et al. (2002) Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. The Journal of Clinical Onkology 20 (20): 4261-4267 68. Davis T.A., Maloney D.G., Grillo-Lopez A.J., White C.A., Williams M.E., Weiner G.J., Dowden S., Levy R. (2000) Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin’s lymphoma with Rituximab and Interferon alpha 2a. Clinical Cancer Research 6:2644-2652 69. Vose J.M., Link B.K., Grossbard M.L., Czuczman M., Grillo-Lopez A.J., Gilman P., Lowe A., Kunkel L.A., Fisher R.I. (2001) Phase II study of Rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin’ lymphoma. The Journal of Clinical Oncology 19 (2): 389-397 70. Czuczman M.S., Grillo-Lopez A.J., White C.A. et al. (1999) Treatment of patient with low grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. The Journal of Clinical Oncology 17: 268-276 71. Jensen M., Winkler U., Manzke O., Diehl V., Engert A. (1998) Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, Rituximab). Annals of Hematology 77:89-91 72. Yang H., Rosove M.H., Figlin R.A. (1999) Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia. American Journal of Hematology 62: 247-250 73. Kunzmann V., Ruediger T., Hallek M., et al. (2001) Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoklonal antibody (IDEC-C2B8, rituximab) treatment. Blood 98: 1991-1992 74. Byrd J.C., Waselenko J.K. Maneatis T.J., Murphy T., Ward F.T., Monahan B.P., Sipe M.A., Donegan S., White C.A. (1999) Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: side effects and rapid blood tumor clearance. The Journal of Clinical Oncology 17 (3): 791-795 75. Winkler U., Jensen M., Manzke O. (1999) Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody. Blood 94: 2217-2224 76. Mosman T. (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. The Journal of Immunological Methods 6:55 77. Hugli T.E. and Müller-Eberhard H.J. (1978) Anaphylatoxins: C3a and C5a. Advances in Immunology 26: 1-53 78. Solomkin J.S., Cotta L.A., Satoh P.S., Hurst J.M., Nelson R.D. (1985) Complement activation and clearance in acute illness and injury: evidence for C5a as a cell-directed mediator of the adult respiratory distress syndrome in man. Surgery 97 (6): 668-678 79. Heidemann M., Hugli T.E. (1984) Anaphylatoxin generation in multisystem organ failure. Journal of Trauma 24 (12): 1038-1043 80. Goldstein I.M., Cala D., Radin A., Kaplan H.B., Horn J., Ranson J. (1978) Evidence of complement catabolism in acute pancreatitis. American Journal of Medicine Science 81. Burger R., Bader A., Kirschfink M., Rother U., Schrod L., Wörner I., Zilow G. (1987) Functional analysis and quatification of the complement C3 derived anaphylatoxin C3a with a monoclonal antibody. Clinical and experimental Immunology 68: 703-711 82. Harjunpää A., Junnikkala S. and Meri S. (2000) Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scandinavian Journal of Immunology 51: 634-641 83. Zilow G., Naser W., Rutz R., Burger R. (1989) Quantitation of the anaphylatoxin C3a in the presence of C3 by novel sandwich ELISA using monoclonal antibody. Journal of Immunological Methods 121: 261-268 84. Batlle Fonrodona F.J., Lopez Fernandez M.F., Vicente Garcia V. et al. (1979) Complement in hematological neoplasias. Allergologia et Immunopathologia.(Madr) 7 (1): 39-46 85. Flieger D., Renoth S., Beier I., Sauerbruch T., Schmidt-Wolf I. (2000) Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC C2B8 in CD20-expressing lymphoma cell lines. Cellular Immunology 204: 55-63 86. Colombat P., Salles G., Brousse N., Eftekhari P., Soubeyran P. et al. (2001) Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 97 (1): 101-106 87. Taji H., Kagami Y., Okada Y., Andou M., Nishi Y., Saito H., Seto M., Morishima Y. (1998) Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody. Japan Journal of Cancer Research 89:748-756 88. Lauria F., Lenoci M., Annino L., Raspadori D. et al. (2001) Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia. Haematologica 86:1046-1050 89. Bellosillo B., Villamor N., Lopez-Guillermo A., Marcè S., Esteve J., et al. (2001) Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by caspase-independent mechanism involving the generation of reactive oxygen species. Blood 98:2771-2777 90. Hagberg H., Lundholm L. (2001) Rituximab, a chimeric anti-CD20 monoclonal antibody, in the treatment of hariy cell leukaemia. British Journal of Haematology 115 (3):609-611 91. Thomas D.A., O’Brien S., Bueso-Ramos C., Faderl S., Keating M.J., et al. (2003) Rituximab in relapsed or refractory hariy cell leukaemia. Blood Jun 19, 92. Nieva J., Bethel K., Saven A. (2003) Phase 2 study of Rituximab in the treatment of cladribine-failed patients with hariy cell leukaemia. 102 (3):810-813 93. Idusogie E.E., Presta L.G., Gazzano-Santoro H., Totpal K., Wong P.W., Ultsch M., Meng G. Mulkerrin M.G. (2000) Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. The Journal of Immunology 164: 4178-4184 94. Morgan B.P., Meri S. (1994) Membrane proteins that protect against complement lysis. Springer Seminars in Immunpathology 15: 369-96 95. Nicholson-Weller A., Burge J., Fearon D.T. et al. (1982) Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertase of the complement system. The Journal of Immunology 129: 184-189 96. Golay J., Zaffaroni L., Vaccari T., Lazzari M., Boleri G.M., Bernasconi S., Tedesco F., Rambaldi A., Introna M. (2000) Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody Rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 95 (12): 3900-3908 97. Treon S.P., Mitsiades C., Mitsiades N., Young G., Doss D., Schlossman R., Anderson K.C. (2001) Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. The Journal of Immunology 24 (3): 265-271 98. Bannerji R., Pearson M., Flinn I.W., Shinn C.A., Goodrich A., Lucas M., Byrd J.C. (2000) Cell surface complement inhibitors CD55 and CD59 may mediate chronic lymphocytic leukemia resistance to Rituximab therapy. Blood 96 (suppl.1): Abstract:706 99. Weng W.K. and R. Levy (2001) Expression of complement inhibitors CD46, CD55 and CD59 on tumor cells does not predict clinical outcome after Rituximab treatment in follicular non-Hodgkin lymphoma. Blood 98 (5): 1352-1357 100. Mathas S., Rickers A., Bommert K., Dörken B., Mapara M.Y. (2000) Anti-CD20 and B-cell receptor-mediated apoptosis: evidence for shared intracellular pathways. Cancer Research 60: 7170-7176 101. Idusogie E.E., Wong P.Y., Presta L.G., Santoro H.G., Totpal K., Ultsch M., Mulkerrin M.G. (2001) Engineered antibodies with increased activity to recruit complement. The Journal of Immunology 166: 2571-2575 102. Takabayashi T., Vannier E., Clark B.D. et al. (1996) A new biologicrole for C3a and C3a-desArg: regulation of tumor necrosis factor α and interleukin 1 β synthesis. The Journal of Immunology 156: 3455-3460 103. Takabayashi T., Vannier E., Burke J.F., Tomkins R.G., Gelfand J.A. Clark B.D. (1998) Both C3a and C3a-desArg regulate interleukin-6 synthesis in human peripheral blood mononuclear cells. The Journal of Infectious Diseases 177: 1622-1628 104. Lugassy G. and Schlesinger M. (1996) The complement system in chronic lymphocytic leukemia: a possible role in autoimmune manifestations. Leukemia and Lymphoma 21: 501-503 105. Varga L., Czink E., Miszlai Z.S., Paloczi K., Banyai A., Szegedi G., Füst G. (1995) Low activity of the classical complement pathway predicts short survival of patients with chronic lymphocytic leukemia. Clinical and experimental Immunology 99: 112-116 106. Czuczman M.S., Fallon A., Acarpace A. et al. (2000) Phase II study of rituximab in combination with fludarabin in patients with low grade or follicular B-cell lymphoma. Blood 96 (suppl.1): Abstract 3154 107. Simonelli C., Tirelli U., Spina M., Vaccher E., Jaeger U., Sparano J. (2001) Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposid (CDE) plus the anti-CD20 monoclonal antibody (rituximab) in HIV-associated non-Hodgkins lymphoma. Preliminary results of an international multicenter trial. ECCO2001: Abstract: 71 108. Coiffier B., Haioun, N., Ketterer A., Engert H., Tilly D., et al. (1998) Rituximab (anti CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 92 (6): 1927-1932 109. National Cancer Institute: Recommendation of Representatives of the NCI’s Clinical Cooperative Groups and the Cancer Treatment Evaluation Program.
Bethesda
, 1988 110. Mey U., Strehl J., Gorschlüter M. et al. (2003) Advances in the treatment of hairy cell leukaemia. The Lancet Oncology 4: 86-94